CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 403-404

  Ford, C D ^a   Asch, J ^a   Konopa, K ^a   Petersen, F B ^a  

^a LDS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; IDARUBICIN; LENALIDOMIDE; STEROID; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CASE REPORT; CHROMOSOME 13Q; CHROMOSOME 22Q; CHROMOSOME 5Q; CHROMOSOME DELETION; CYTOGENETICS; DIARRHEA; DRUG ERUPTION; ERYTHEMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LETTER; METAPHASE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SKIN BIOPSY;

AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; RECURRENCE; THALIDOMIDE;

EID: 76749168445     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.146     Document Type: Letter

References (7)

1. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557.
2. Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5) (q13q33) myelodysplastic syndrome. Leukemia 2006; 20: 2063-2064.
3. Lancet JF, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007; 21: 586-588.
4. Penarrubia MJ, Silvestre LA, Conde J, Cantalapiedra A, Garcia Frade LJ. Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion. Leuk Res 2009; 33: e8-e9.
5. Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005; 35: 165-169.
6. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009; 23: 605-607.
7. Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009; 113: 1002-1005.